GARP Research Downgrades Qiagen NV (QGEN) to Neutral On Multiple Headwinds

GARP Research downgraded Qiagen NV (NASDAQ: QGEN) from Buy to Neutral, citing several headwinds.

The firm said the most significant headwind is increasing competition for HPV testing.

"The Digene franchise has provided more than half of Qiagen’s pre-tax earnings growth since its 2007 acquisition, we estimate, analyst Diron Tappin stated. "Hologic's (Nasdaq: HOLX) manual assay is already stealing share, and the pending automated solutions from Gen-Probe (Nasdaq: GPRO) and Roche could inflict more damage. Moreover, the expiration of COBRA subsidies for 400,000 U.S. households in 1Q11 could put unexpected pressure on HPV sales as women defer routine Ob-Gyn visits," he continued.

For more ratings news on Qiagen NV click here and for the rating history of Qiagen NV click here.

Shares of Qiagen NV closed at $20.26 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
• Reading (RDI) Tops Q2 EPS by 4c